Production (Stage)
Arcadia Biosciences, Inc.
RKDA
$4.28
$0.102.39%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 21.58% | 56.50% | 18.41% | 0.69% | -19.89% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 21.58% | 56.50% | 18.41% | 0.69% | -19.89% |
| Cost of Revenue | 44.80% | 1,886.11% | 26.87% | -5.02% | -55.01% |
| Gross Profit | 0.39% | -29.52% | 3.42% | 6.94% | 178.92% |
| SG&A Expenses | -15.71% | 56.60% | 20.32% | 29.36% | -49.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.69% | 94.58% | 22.34% | 20.90% | -50.39% |
| Operating Income | 21.39% | -126.06% | -25.98% | -38.93% | 60.06% |
| Income Before Tax | 374.45% | -805.39% | -84.98% | -41.38% | 89.71% |
| Income Tax Expenses | -- | 14.29% | -- | -- | -- |
| Earnings from Continuing Operations | 374.45% | -793.14% | -84.98% | -41.36% | 89.71% |
| Earnings from Discontinued Operations | -- | 98.88% | 77.70% | 66.24% | -715.47% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 207.26% | -42.45% | 37.20% | 28.92% | 74.18% |
| EBIT | 21.39% | -126.06% | -25.98% | -38.93% | 60.06% |
| EBITDA | 19.59% | -139.09% | -34.02% | -43.19% | 60.66% |
| EPS Basic | 206.92% | -42.11% | 37.40% | 28.49% | 83.61% |
| Normalized Basic EPS | 192.90% | -1,913.96% | -84.38% | -167.73% | 93.73% |
| EPS Diluted | 206.50% | -42.11% | 37.40% | 28.49% | 83.57% |
| Normalized Diluted EPS | 192.90% | -1,913.96% | -84.38% | -167.73% | 93.73% |
| Average Basic Shares Outstanding | 0.32% | 0.24% | 0.32% | 0.32% | 57.53% |
| Average Diluted Shares Outstanding | 0.33% | 0.24% | 0.32% | 0.32% | 57.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |